Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma

Abstract

Although melanoma is one of the most immunogenic tumors, it has an ability to evade anti-tumor immune responses by exploiting tolerance mechanisms, including negative immune checkpoint molecules. The most extensively studied checkpoints represent cytotoxic T lymphocyte-associated protein-4 (CTLA-4) and programmed cell death protein 1 (PD-1). Immune checkpoint inhibitors (ICI), which were broadly applied for melanoma treatment in the past decade, can unleash anti-tumor immune responses and result in melanoma regression. Patients responding to the ICI treatment showed long-lasting remission or disease control status. However, a large group of patients failed to respond to this therapy, indicating the development of resistance mechanisms. Among them are intrinsic tumor properties, the dysfunction of effector cells, and the generation of immunosuppressive tumor microenvironment (TME). This review discusses achievements of ICI treatment in melanoma, reasons for its failure, and promising approaches for overcoming the resistance. These methods include combinations of different ICI with each other, strategies for neutralizing the immunosuppressive TME and combining ICI with other anti-cancer therapies such as radiation, oncolytic viral, or targeted therapy. New therapeutic approaches targeting other immune checkpoint molecules are also discussed.

Tumor Lysis Syndrome After a Single Dose of Atezolizumab with Nab-Paclitaxel: A Case Report and Review of Literature

“…Modern advances in immunotherapy have shifted the treatment approach for multiple solid tumors. Immunotherapy is now the first-line treatment for metastatic melanoma, renal cell carcinoma, and lung cancer [ 17 – 19 ]. In March 2019, a new combination therapy composed of the anti-PD-L1 antibody atezolizumab and protein-bound paclitaxel received full Food and Drug Administration approval for patients with mTNBC.…”

Stromal Cells Present in the Melanoma Niche Affect Tumor Invasiveness and Its Resistance to Therapy

“…ECM remodeling is also promoted by FAP, a member of the serine protease family, overexpressed by activated fibroblasts ( Figure 3 ) [ 94 , 95 ]. FAP is also thought to suppress T cell recruitment and function and, therefore, support melanoma immune escape [ 96 , 97 ]. Moreover, it was confirmed that the loss of β-catenin expression in CAFs correlates with a decrease in fibronectin and collagen levels in the tumor stroma.…”

Is There a Place for Immune Checkpoint Inhibitors in Vulvar Neoplasms? A State of the Art Review

“…Furthermore, a substantial fraction of long-term survivors seems to remain disease-free even after discountinuation of treatment. In fact, ICI-based immunotherapy is approved by the FDA as a standard treatment for patients with advanced or recurrent melanoma [ 116 , 117 , 118 ].…”